Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Barbara C. M. Potts"'
Autor:
Yoshiki Hayashi, Yoshiaki Kiso, Takumi Chinen, Saskia T. C. Neuteboom, Yuri Yamazaki, Fumika Yakushiji, Barbara C. M. Potts, Yurika Masuda, G. K. Lloyd, Michael A. Palladino, Hiroyuki Yasui, Makiko Sumikura, Yoshio Hayashi, Takeo Usui
Publikováno v:
Bioorganic & Medicinal Chemistry. 20:4279-4289
KPU-105 (4), a potent anti-microtubule agent that contains a benzophenone was derived from the diketopiperazine-type vascular disrupting agent (VDA) plinabulin 3, which displays colchicine-like tubulin depolymerization activity. To develop derivative
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78e756455eedc08eae19c44338fc4755
https://doi.org/10.1016/j.bmc.2012.05.059
https://doi.org/10.1016/j.bmc.2012.05.059
Autor:
Akiko Oda, Gordafaried Deyanat-Yazdi, Brian R. Miller, Takayoshi Kitagawa, Yoshio Hayashi, Takeo Usui, Barbara C. M. Potts, Sumie Orikasa, Yoshiaki Kiso, Yuki Shinozaki, Takumi Chinen, Yuri Yamazaki, Fumika Yakushiji, Miki Akamatsu, Saskia T. C. Neuteboom, G. K. Lloyd, Kaneo Kanoh, Benjamin Nicholson, Hiroyuki Yasui, Koji Tanaka, Michael A. Palladino, Tomoko Yoshida
Publikováno v:
Journal of Medicinal Chemistry. 55:1056-1071
Plinabulin (11, NPI-2358) is a potent microtubule-targeting agent derived from the natural diketopiperazine "phenylahistin" (1) with a colchicine-like tubulin depolymerization activity. Compound 11 was recently developed as VDA and is now under phase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e08db2de8e15dab780cbc1ea466ba863
https://doi.org/10.1021/jm2009088
https://doi.org/10.1021/jm2009088
Autor:
Irene M. Ghobrial, KC Anderson, Saskia T. C. Neuteboom, E. Valashi, G. K. Lloyd, William H. McBride, Paul G. Richardson, Barbara C. M. Potts, Joya Chandra, Huib Ovaa, Michael A. Palladino, Callum M. Sloss, Michael Groll, William Fenical, Aldo M. Roccaro, Frank Pajonk, Anas Younes, Y. Oki, James C. Cusack, Paul R. Jensen, Celia R. Berkers, Claudia P. Miller, M. X. Albitar, Stavroula Baritaki, Kin S. Lam, David J. McConkey, Ben Bonavida, D Chauhan, Matthew A. Spear
Publikováno v:
Current Cancer Drug Targets. 11:254-284
The proteasome has emerged as an important clinically relevant target for the treatment of hematologic malignancies. Since the Food and Drug Administration approved the first-in-class proteasome inhibitor bortezomib (Velcade®) for the treatment of r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab2ae9e187e8864778eee530baefda2b
https://doi.org/10.2174/156800911794519716
https://doi.org/10.2174/156800911794519716
Autor:
G. K. Lloyd, Ajita V. Singh, Barbara C. M. Potts, Michael A. Palladino, Kenneth C. Anderson, Dharminder Chauhan
Publikováno v:
British Journal of Haematology. 149:550-559
Our previous study showed that the novel proteasome inhibitor NPI-0052 induces apoptosis in multiple myeloma (MM) cells resistant to conventional and bortezomib (Velcade, Takeda, Boston, MA, USA) therapies. In vivo studies using human MM-xenografts d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::efe0de85da0fa688a1d5785c67107912
https://doi.org/10.1111/j.1365-2141.2010.08144.x
https://doi.org/10.1111/j.1365-2141.2010.08144.x
Autor:
Kin S. Lam, Barbara C. M. Potts
Publikováno v:
Marine Drugs
Marine Drugs, Vol 8, Iss 4, Pp 835-880 (2010)
Marine Drugs, Vol 8, Iss 4, Pp 835-880 (2010)
The salinosporamides are potent proteasome inhibitors among which the parent marine-derived natural product salinosporamide A (marizomib; NPI-0052; 1) is currently in clinical trials for the treatment of various cancers. Methods to generate this clas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93d10d1872f8929262f5e524c44942bf
http://europepmc.org/articles/PMC2866466
http://europepmc.org/articles/PMC2866466
Autor:
Venkat R. Macherla, Katherine A. McArthur, Barbara C. M. Potts, Rama Rao Manam, Michael Groll
Publikováno v:
Journal of Medicinal Chemistry. 52:5420-5428
Many marketed drugs contain fluorine, reflecting its ability to modulate a variety of biological responses. The unique 20S proteasome inhibition profile of fluorosalinosporamide compared to chlorinated anticancer agent salinosporamide A (NPI-0052) is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a4a9b704fd993b8cf996a1a138e9c31
https://doi.org/10.1021/jm900559x
https://doi.org/10.1021/jm900559x
Publikováno v:
Tetrahedron Letters. 48:2537-2540
Salinosporamide A (NPI-0052, 1), a highly potent 20S proteasome inhibitor, has been prepared from its ketone precursor (2) by asymmetric enzymatic reduction. The yields are quantitative with complete stereoselective conversion to the desired product,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e29ae186b3327d43d0753d18d60afa67
https://doi.org/10.1016/j.tetlet.2007.02.017
https://doi.org/10.1016/j.tetlet.2007.02.017
Autor:
Saskia T. C. Neuteboom, Scott S Mitchell, Barbara C. M. Potts, Jianlin Xu, Gordafaried Deyanat-Yazdi, Sy Teisan, Ta-Hsiang Chao, Katherine Anne Reed, Rama Rao Manam, Kin S. Lam
Publikováno v:
Journal of Natural Products. 70:269-276
Salinosporamide A (NPI-0052; 3), a highly potent inhibitor of the 20S proteasome, is currently in phase I clinical trials for the treatment of cancer. During the course of purifying multigram quantities of 3 from Salinispora tropica fermentation extr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d3effc54d9880cd0e7e895ffdb1e4c4
https://doi.org/10.1021/np0603471
https://doi.org/10.1021/np0603471
Autor:
Ginger Tsueng, Jianlin Xu, Scott S Mitchell, Barbara C. M. Potts, Katherine A. McArthur, Kin S. Lam
Publikováno v:
The Journal of Antibiotics. 60:13-19
We examined the effects of halogens on the production of salinosporamide A (NPI-0052) by the obligate marine actinomycete Salinispora tropica NPS465, specifically the production of analogs containing halogens other than chlorine. Adding NaF, NaBr and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6251ce366f3e451896c1f6109d721ed3
https://doi.org/10.1038/ja.2007.2
https://doi.org/10.1038/ja.2007.2
Autor:
Gordafaried Deyanat-Yazdi, Ta-Hsiang Chao, Paul R. Jensen, Bao Mai, Kin S. Lam, Barbara C. M. Potts, Michael A. Palladino, William Fenical, Saskia T. C. Neuteboom, Katherine Anne Reed, Benjamin Nicholson, Scott S Mitchell, Rama Rao Manam, Venkat R. Macherla
Publikováno v:
Journal of Medicinal Chemistry. 48:3684-3687
Salinosporamide A (1, NPI-0052) is a potent proteasome inhibitor in development for treating cancer. In this study, a series of analogues was assayed for cytotoxicity, proteasome inhibition, and inhibition of NF-kappaB activation. Marked reductions i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cb6efcee18907297287cfa16b47c94b4
https://doi.org/10.1021/jm048995+
https://doi.org/10.1021/jm048995+